TABLE 2.

The Impact of PCSK9 Inhibitor Use on Health Outcome at Age 51

	Status quo	PCSK9 inhibitor Scenario I - Current Eligibility			PCSK9 inhibitor Scenario II - Extended Eligibility
	Mean	Mean	Difference*	95% CI	Mean	Difference*	95% CI
Health outcomes, at age 51**
Life expectancy, years	30.9	32.0	1.1	[0.9, 1.4]	32.7	1.9	[1.5, 2.3]
Disability-free life expectancy, years	22.9	23.2	0.4	[0.3, 0.5]	23.6	0.8	[0.6, 1.0]
Quality-adjusted life years (QALYs)	25.5	26.1	0.6	[0.4, 0.8]	26.7	1.2	[0.9, 1.5]
Cumulative disease incidence at age 79 (per thousand)†
Heart Disease	419.3	411.6	−7.7	[−0.9, −14.7]	379.0	−40.3	[−35.5, −69.8]
Stroke	207.2	219.0	11.8	[5.0, 18.9]	222.3	15.0	[6.3, 23.4]
Diabetes	473.8	479.5	5.7	[1.7, 9.9]	483.0	9.2	[2.4, 14.5]
Hypertension	732.4	737.6	5.2	[0.3, 11.8]	742.2	9.8	[1.7, 14.9]
Cancer	285.5	294.8	9.4	[4.0, 16.3]	299.9	14.4	[7.0, 21.3]

Current Eligibility refers to the current FDA-approved eligibility criteria for PCSK9 inhibitors. Extended Eligibility refers to using PCSK9 inhibitors as primary prevention therapy for those without clinical CVD but who possess CVD high-risk equivalents.

^*The result differences compared with the status quo scenario.

^**The results were calculated from age 51 until death.

^†Total incidence before age 79 for a 1,000 individuals without the disease at age 51. Disability-free life expectancy refers to reporting no instrumental activity of daily living or activity of daily living limitations and not living in a nursing home. Quality-adjusted life-years adjust length of life for quality based on a person’s chronic conditions and functional status. 95% confidence intervals of the difference estimates are presented in brackets, indicating the uncertainty of the effectiveness of PCSK9 inhibitors. The 95% confidence intervals for the mean values in each scenario can be found in the Supplemental Appendix.